Antithrombotic Agents in Coronary Artery Disease

Cairns, John A.; Théroux, Pierre; Lewis, H. Daniel; Ezekowitz, Michael D.; Meade, T. W.; Sutton, George C.

doi:10.1378/chest.114.5_supplement.611s

Cited by 89 publications

(58 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Platelets appear to be the predominant source of circulating sCD40L (5). The elevated plasma levels of sCD40L in unstable angina and during PCI in the absence of GP IIb/IIIa antagonist therapy (4), therefore, are of particular relevance to the presently described inhibition of sCD40L release from platelets by GP IIb/IIIa antagonists (abciximab, eptifibatide, tirofiban), because these agents are now standard therapy for unstable angina (24) and during PCI (25). The sCD40L is only released when platelets are activated (4 -6), that is, at sites of local thrombosis.…”

Section: Discussionmentioning

confidence: 99%

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Furman

Krueger

Linden

et al. 2004

Journal of the American College of Cardiology

119

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Furman

Krueger

Linden

et al. 2004

Journal of the American College of Cardiology

119

View full text Add to dashboard Cite

show abstract

“…Warfarin has also been beneficial in preventing stroke during the first 3 months after MI (116,117) (Table 4), although aspirin is more commonly used for long-term prophylaxis (86). A meta analysis of 5 major trials that used warfarin in post-MI patients revealed that warfarin reduced the risk of stroke by 64%, but the benefit was unclear in patients older than 75 years (118). Current guidelines suggest that warfarin should be used to prevent stroke after MI in patients with atrial fibrillation, left ventricle thrombi, or compromised left ventricular function (119).…”

Section: Anticoagulation Therapymentioning

confidence: 99%

Drug Therapy of Neurovascular Disease

Weinberger

Frishman²,

Terashita³

2003

Cardiology in Review

View full text Add to dashboard Cite

Recent advances in the prevention and pharmacotherapy of cerebrovascular disease have provided more favorable clinical outcomes. For the treatment of an acute ischemic stroke, the early use of thrombolytic agents can reduce the degree of brain damage while improving functional outcomes. However, trials evaluating various classes of other neuroprotective agents have not shown benefit to date. For the prevention of second stroke, the use of antiplatelet drugs, HMG-CoA reductase inhibitors, and angiotensin-converting enzyme inhibitors with a diuretic have shown benefit in reducing new events. In patients with underlying heart disease or atrial fibrillation, warfarin appears to be the drug of choice in preventing stroke. Early treatment of hemorrhagic stroke with calcium channel blockers can improve the functional outcome. Innovative therapies are now available for the treatment of migraine and vascular dementia. Primary prevention of stroke remains the optimal therapeutic strategy and includes treatment of systemic hypertension and hypercholesterolemia.

show abstract

“…First, although it is very apparent that aspirin is effective in preventing vascular death and other vascular events when administered early after acute coronary events, the data are more limited and less convincing when taken from trials in which aspirin was initiated in patients with chronic CAD who have not had recent acute coronary events or symptomatic angina. As a result, the most recent American College of Chest Physicians Consensus Conference on Antithrombotic Therapy provided only a weak recommendation for aspirin in patients with chronic CAD (level of evidence 2C) (6). This is the group in which CHF patients with CAD most commonly fall.…”

Section: Is Aspirin Beneficial In Chf Patients?mentioning

confidence: 99%

Aspirin Use in Chronic Heart Failure

Massie

2005

Journal of the American College of Cardiology

View full text Add to dashboard Cite

There has been ongoing controversy as to whether aspirin should be used in patients with chronic heart failure (CHF). The argument for aspirin is that many patients have underlying coronary disease, and aspirin prevents reinfarction and other vascular events. Arguments against the routine use of aspirin are that many CHF patients do not have underlying coronary disease, and that the benefit of aspirin lessens after the first 6 to 12 months after infarction. Also, several analyses suggest that aspirin may actually worsen outcomes in CHF patients, possibly because it inhibits prostaglandins, with resulting adverse hemodynamic and renal effects. Two recent prospective randomized studies have found that aspirin is associated with more frequent hospitalizations for worsening heart failure, although it did not have an adverse effect on vascular events. These results suggest that aspirin should not be routinely used in CHF patients and be avoided in those with refractory CHF, but that it may be beneficial in patients with recent infarction or multiple vascular risk factors.

show abstract

Antithrombotic Agents in Coronary Artery Disease

Abstract: ach year in the United States there are about 1 million "heart attacks"-a term that includes both acute infarction and sudden cardiac death.' Nearly Medical Research Council Trial:'3 This study was

Cited by 89 publications

References 135 publications

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Drug Therapy of Neurovascular Disease

Aspirin Use in Chronic Heart Failure

Contact Info

Product

Resources

About